Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMA study of pembrolizumab for unresectable non-metastatic dMMR colorectal cancer
NL-OMON51364Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Objective response rate. Started Dec 2022; status: recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON51364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51364.